Bristol-Myers Squibb Co.

24. Sept. 2026, 23:05 UTC

Bristol-Myers Squibb Co is trading modestly lower in after-market hours, reflecting broader market declines amid geopolitical tensions and uncertainty in trade discussions.

23. Sept. 2026, 23:01 UTC

Bristol-Myers Squibb Co is trading modestly higher in after-market hours, following notable fluctuations earlier in the session.

22. Sept. 2026, 23:01 UTC

Bristol-Myers Squibb Co is trading modestly higher in after-market hours, continuing upward momentum from Tuesday's close despite notable fluctuations during the session.

21. Sept. 2026, 20:06 UTC

Bristol-Myers Squibb Co shares fell, remaining near the lower end of their one-month range and below the 20-day moving average amid broader market weakness.

19. Sept. 2026, 00:02 UTC

Bristol-Myers Squibb Co is trading roughly flat in after-market hours, following a minor decline and amid a broader trend of lower finishes over the past four sessions.

18. Sept. 2026, 23:01 UTC

Bristol-Myers Squibb Co is trading lower in after-market hours, continuing a trend of declines seen over the past four sessions.

17. Sept. 2026, 23:01 UTC

Bristol-Myers Squibb Co's stock is modestly higher in after-market trading following positive Phase 3 results for Sotyktu in treating active psoriatic arthritis.

16. Sept. 2026, 23:36 UTC

Bristol-Myers Squibb Co is trading lower in after-market hours, positioned notably below its 20-day moving average and near the lower end of its one-month range.

15. Sept. 2026, 23:41 UTC

Bristol-Myers Squibb shares are lower in after-market trading, reflecting negative sentiment linked to a significant drop in the New York Empire State Manufacturing Index.

14. Sept. 2026, 19:26 UTC

Advancing amid favorable market conditions, State Street Health Care ETF rises.

10. Sept. 2026, 19:16 UTC

Bristol-Myers Squibb shares are lower as HSBC raises price target to $65.00 while maintaining a Hold rating amid ongoing market sentiment.

9. Sept. 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, marking a potential rebound after three sessions of declines. No specific news was identified.

8. Sept. 2026, 23:06 UTC

Bristol-Myers Squibb Co reported positive Phase 2 trial results for arlocabtagene autoleucel, contributing to shares advancing in after-market trading.

4. Sept. 2026, 22:14 UTC

Bristol-Myers Squibb Co shares are lower in after-market trading following the FDA's withdrawal of Krazati's accelerated approval for colorectal cancer.

3. Sept. 2026, 21:51 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, declining since Thursday's close amid a broader market rally and no specific company news.

2. Sept. 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. Broader market sentiment is affected by rising oil prices amid U.S.-Iran tensions.

1. Sept. 2026, 23:06 UTC

Bristol-Myers Squibb shares declined after market close, mirroring a broader downturn in the pharmaceutical sector amid rising oil prices and inflation concerns.

31. Aug. 2026, 20:07 UTC

Bristol-Myers Squibb shares are higher following positive long-term data on Camzyos presented at the European Society of Cardiology Congress, showing significant patient improvements.

28. Aug. 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rebounding from three consecutive lower sessions with no specific news identified.

27. Aug. 2026, 19:36 UTC

Bristol-Myers Squibb shares are lower today amid broader market concerns over rising inflation and potential Federal Reserve interest rate hikes.

26. Aug. 2026, 23:16 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the decline following a routine session.

25. Aug. 2026, 23:21 UTC

Bristol-Myers Squibb Co shares are lower in after-market trading, influenced by a decline in the pharmaceutical sector and falling crude oil prices.

24. Aug. 2026, 23:41 UTC

Bristol-Myers Squibb shares are trading lower in after-market hours amid weak market conditions and heightened geopolitical tensions affecting overall investor sentiment.

21. Aug. 2026, 20:02 UTC

Bristol-Myers Squibb Co is higher today following reports of a collaboration with Chai on antibody discovery, enhancing its drug development capabilities.

20. Aug. 2026, 20:01 UTC

Bristol-Myers Squibb shares are lower amid a significant decline in the Pharmaceuticals sub-sector, despite recent FDA approval for its multiple myeloma drug.

19. Aug. 2026, 23:21 UTC

Bristol-Myers Squibb Co shares are higher in after-market hours, fluctuating between a low of -0.28% and a high of 0.50% since Wednesday's close.

18. Aug. 2026, 19:46 UTC

Bristol-Myers Squibb is using AI tools to cut clinical trial development times, trading higher amid positive market sentiment surrounding these advancements.

17. Aug. 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market trading amid broader market concerns and unusual selling pressure, though no specific news was identified.

14. Aug. 2026, 20:06 UTC

Bristol-Myers Squibb shares are lower after FDA approval of Zenbexus due to concerns over its $29,500 pricing, which may dampen market sentiment.

13. Aug. 2026, 23:56 UTC

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.